EMD Serono Chief Financial Officer Named to South Shore Hospital Board of Directors

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is proud to announce that Lisa Costantino, Chief Financial Officer (CFO), has been appointed to the South Shore Hospital Board of Directors. Her term on the board began on Aug 1, 2013.

“We are truly delighted that Lisa Costantino has joined our Board”

“We are truly delighted that Lisa Costantino has joined our Board,” said Kenneth Kirkland, South Shore Hospital Board Chairman and Managing Partner of KAF Financial Group. Buy Tricor (Fenofibrate) without prescription “Her professional expertise – coupled with her strong commitment to our charitable mission – will make her an asset to our governing body.”
Costantino started with EMD Serono more than 30 years ago as an accounts payable clerk and held positions of increasing responsibility until being appointed as CFO in 2009.
In her role as CFO, Costantino’s responsibilities include the oversight and strategic direction-setting of the financial framework within the US organization. Buy Cartia Xt (Diltiazem Hcl) tabs online without prescription In addition, she is responsible for collaborating with a variety of global functions across the business.
She has been a key contributor to a number of important strategic initiatives for the company, including the acquisition of Serono by Merck KGaA, Darmstadt, Germany.
Costantino was recognized by the Boston Business Journal as its 2010 CFO of the Year, and was named to the PharmaVOICE 100 list of Most Inspiring People in 2012. Buy Cartia (Diltiazem Hcl) pills online without prescription Additionally, Costantino received the CEO Award from EMD Serono in 2003 and the President’s Award from EMD Serono in 2006.
Throughout her career, Costantino has been an active community member, working with organizations such as the National Multiple Sclerosis Society, Boys and Girls Club of America, Home for Little Wanderers, and Magical Moon Foundation among others. Costantino holds a bachelor of science in accounting from the University of Massachusetts, and an MBA from Suffolk University.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. Buy Vitamins online The company has strong market positions in neurodegenerative diseases, endocrinology and in reproductive health. In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 15 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.

About Merck KGaA
Merck is a leading pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Doctor Online Consultation Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

EMD Serono Chief Financial Officer Named to South Shore Hospital Board of Directors

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta^®). The CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the once daily dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, on cardiovascular and renal microvascular outcomes in adults with Type 2 Diabetes at risk of cardiovascular and renal events.
Linagliptin (5 mg, once daily) is a once-daily tablet that is used along with diet and exercise and other drug therapies to improve glycaemic control in adults with Type 2 Diabetes.
“Diabetes is a major risk factor for cardiovascular disease, as well as a leading cause of chronic renal failure,” said Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City in Dallas and Principal Investigator of the study. Buy Voltaren (Diclofenac Sodium) pills online without prescription “CARMELINA will investigate both cardiovascular and renal safety with a DPP-4 inhibitor on adverse cardiovascular and renal outcomes.”
The CARMELINA study will include more than 8,000 adults with Type 2 Diabetes in 24 countries at more than 500 sites around the world. The primary endpoint will be time to the first occurrence of either CV death (including fatal stroke and fatal MI); non-fatal MI; non-fatal stroke; or hospitalisation for unstable angina pectoris (AP). Buy Volmax Cr (Albuterol, Salbutamol) tabs online without prescription The renal outcome is measured as a composite of renal death, sustained end-stage renal disease and sustained decrease of ≥50 percent eGFR. The study is expected to complete in 2018.
“We are delighted that the first patient has now been enrolled in CARMELINA and look forward to continued recruitment and patient follow-up,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. Buy Propecia (Finasteride) without prescription “The initiation of this trial reinforces our ongoing commitment to evaluate the efficacy and safety of linagliptin, ensuring that treating physicians are provided with all required information to support the use of the treatment in clinical practice as appropriate.”
About CARMELINA
CARMELINA (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) is a long-term study investigating the efficacy and safety of linagliptin 5 mg once daily versus placebo on cardiovascular and renal microvascular outcomes in people with Type 2 Diabetes who are at risk of cardiovascular events. Buy Vitamins online Adults with Type 2 Diabetes and previous CV complications and albuminuria (UACR ≥30mg/g) and/or evidence of microvascular related end-organ damage (eGFR 15-<45 with any UACR or eGFR ≥45-75 with an UACR >200mg/g) will be randomised into the study.
About Linagliptin
Linagliptin is marketed in Europe as Trajenta^® (linagliptin) and in the U.S. as Tradjenta^® (linagliptin tablets), as a once-daily tablet (5mg) that is used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).